June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Influence of the Vitreomacular Interface on Treatment Outcomes in the Comparison of AMD Treatments Trials (CATT)
Author Affiliations & Notes
  • Thomas A Ciulla
    Retina Service, Midwest Eye Institute, Indianapolis, IN
  • Gui-Shuang Ying
    Ophthalmology, University of Pennsylvania, Philadelphia, PA
  • Maureen G Maguire
    Ophthalmology, University of Pennsylvania, Philadelphia, PA
  • Daniel F Martin
    Cole Eye Institute, Cleveland Clinic, Cleveland, OH
  • Glenn J Jaffe
    Ophthalmology, Duke University, Raleigh, NC
  • Juan E Grunwald
    Ophthalmology, University of Pennsylvania, Philadelphia, PA
  • Ebenezer Daniel
    Ophthalmology, University of Pennsylvania, Philadelphia, PA
  • Cynthia A Toth
    Ophthalmology, Duke University, Raleigh, NC
  • Footnotes
    Commercial Relationships Thomas Ciulla, Thombogenics (C); Gui-Shuang Ying, None; Maureen Maguire, Genentech (C); Daniel Martin, None; Glenn Jaffe, Alcon (C), Heidelberg Engineering (C); Juan Grunwald, None; Ebenezer Daniel, None; Cynthia Toth, Alcon (P), Bioptigen (F), Genentech (F)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 3154. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Thomas A Ciulla, Gui-Shuang Ying, Maureen G Maguire, Daniel F Martin, Glenn J Jaffe, Juan E Grunwald, Ebenezer Daniel, Cynthia A Toth, ; Influence of the Vitreomacular Interface on Treatment Outcomes in the Comparison of AMD Treatments Trials (CATT). Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):3154.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

To assess the association of the vitreomacular interface (VMI) with outcomes in eyes treated with anti-VEGF drugs for neovascular age-related macular degeneration (AMD).

 
Methods
 

A prospective cohort study of the VMI in neovascular AMD was carried out within the<br /> Comparison of AMD Treatments Trials (CATT). In this multicenter randomized clinical trial, treatment was assigned randomly to either ranibizumab or bevacizumab and to 3 different regimens for dosing over a two-year period. Masked graders at a reading center assessed optical coherence tomography (OCT) scans at baseline and follow-up for vitreomacular traction (VMT) and adhesion (VMA), fluid and central thickness. Visual acuity (VA) was measured by masked, certified examiners. VA and anatomical features at baseline, 1 and 2 years, as well as number of treatments were compared between groups defined by VMT/VMA status at baseline or during follow-up.

 
Results
 

At baseline, 143 (12.8%) patient eyes had VMT or VMA. Compared to those with neither (N=972), patients with VMT or VMA were younger (mean (SE): 75.5 ±0.6 versus 79.7 ± 0.24 years, p<0.0001), more likely to be male (52.4% versus 36.2%, p=0.0003), cigarette smokers (68.5% versus 55.3%, p=0.003), and to have subretinal fluid on OCT (86.7% versus 81.0%, p=0.047). VMI status was not associated with VA at baseline or follow-up. Among eyes treated as needed (PRN, n=598) and followed for 2 years(n=516), the mean number of injections over 2 years was 15.4 ±0.9 for eyes having VMT at baseline or during follow-up (n=60), 13.8 ±0.7 for eyes with VMA at baseline or follow-up (n=79), and 12.9 ±0.4 (p=0.02) for eyes without VMT or VMA (n=377). In addition, the mean number of injections in eyes treated PRN increased from 13.0 ±0.3 when VMT was not observed, to 13.6 ±1.3 when observed once, to 17 ±1.2 when observe more than once during follow-up. At 2 years, geographic atrophy developed in a lower percentage of eyes with VMT or VMA at baseline (11.7%) than with neither condition (22.5%, p=0.005).

 
Conclusions
 

VMT and VMA were infrequent in eyes in the CATT. At baseline and follow-up, VMT or VMA were not associated with VA. Eyes with VMT or VMA treated PRN required on average 2 more injections over 2 years.

 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×